Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Mithra Pharmaceuticals S.A. - Filing #3183078

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	296,552,000 EUR	—	—	—	—	—	322,528,000 EUR	—	—	—	—	—
Current assets	145,863,000 EUR	—	—	—	—	—	99,389,000 EUR	—	—	—	—	—
Non-current liabilities	278,298,000 EUR	—	—	—	—	—	292,285,000 EUR	—	—	—	—	—
Current liabilities	130,431,000 EUR	—	—	—	—	—	95,793,000 EUR	—	—	—	—	—
Revenue	—	—	—	66,997,000 EUR	—	—	—	—	—	—	22,668,000 EUR	—
Profit (loss)	—	—	—	59,620,000 EUR	59,620,000 EUR	—	—	—	—	—	116,875,000 EUR	116,875,000 EUR
Other comprehensive income	—	—	—	18,298,000 EUR	—	—	—	—	—	—	17,300,000 EUR	—
Comprehensive income	—	- EUR	18,298,000 EUR	77,918,000 EUR	59,620,000 EUR	- EUR	—	17,300,000 EUR	- EUR	- EUR	134,175,000 EUR	116,875,000 EUR